Neuraxis Schuld

Wat doet Neuraxis? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is een van de meest populaire bedrijven op Eulerpool.